Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019048540) SALMONELLA SIIE-DERIVED PEPTIDES FOR MANIPULATION OF LONG-LIVED PLASMA CELLS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/048540 International Application No.: PCT/EP2018/073992
Publication Date: 14.03.2019 International Filing Date: 06.09.2018
IPC:
C07K 14/255 (2006.01) ,A61K 38/04 (2006.01) ,A61K 38/16 (2006.01) ,C07K 7/04 (2006.01) ,C12N 1/36 (2006.01) ,C07K 14/225 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195
from bacteria
24
from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
255
Salmonella (G)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
7
Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04
Linear peptides containing only normal peptide links
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1
Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
36
Adaptation or attenuation of cells
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
195
from bacteria
225
from Alcaligenes (G)
Applicants:
DEUTSCHES RHEUMA-FORSCHUNGSZENTRUM BERLIN [DE/DE]; Charitéplatz 1 10117 Berlin, DE
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY [JP/JP]; 1-33 Yayoi-cho Inage-ku Chiba-shi Chiba, 263-8522, JP
Inventors:
TOKOYODA, Koji; DE
TAKAYA, Akiko; JP
Agent:
HERTIN UND PARTNER; Kurfürstendamm 54/ 55 10707 Berlin, DE
Priority Data:
17190133.308.09.2017EP
17199568.101.11.2017EP
Title (EN) SALMONELLA SIIE-DERIVED PEPTIDES FOR MANIPULATION OF LONG-LIVED PLASMA CELLS
(FR) PEPTIDES DÉRIVÉS D'UN SITE DE SALMONELLA POUR LA MANIPULATION DE CELLULES PLASMATIQUES À LONGUE DURÉE DE VIE
Abstract:
(EN) The invention relates to an isolated polypeptide comprising or consisting of an amino acid sequence according to SEQ ID NO 1 (AS 136-154) (EEAEKAKEAAEKALNEAFE) or an amino acid sequence with a sequence identity of least 70 %, preferably of at least 80 %, more preferably of at least 90 % to SEQ ID NO 1, wherein the polypeptide is no longer than 200, preferably no longer than 170 amino acids. The invention relates to a nucleic acid encoding for said polypeptide, a gene therapy vector comprising said nucleic acid and genetically modified cells expressing said polypeptide. Furthermore, the invention relates to the medical use of said polypeptide, said nucleic acid, said gene therapy vector and/or said cell for the treatment of a disease associated with pathogenic long-lived plasma cells.
(FR) L'invention concerne un polypeptide isolé comprenant ou consistant en une séquence d'acides aminés selon SEQ ID NO 1 (AS 136-154) (EEAEKAKEAAEKALNEAFE) ou d'une séquence d'acides aminés ayant une identité de séquence d'au moins 70 %, de préférence d'au moins 80 %, de préférence encore d'au moins 90 % à SEQ ID NO 1, le polypeptide ayant une longueur maximale de 200, de préférence une longueur maximale de 170 acides aminés. L'invention concerne un acide nucléique codant pour ledit polypeptide, un vecteur de thérapie génique comprenant ledit acide nucléique, et des cellules génétiquement modifiées exprimant ledit polypeptide. L'invention concerne en outre, l'utilisation médicale dudit polypeptide, dudit acide nucléique, dudit vecteur de thérapie génique et/ou de ladite cellule dans le traitement d'une maladie associée à des cellules plasmatiques pathogènes à longue durée de vie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)